Mirxes Holding Company Limited 股份代號 : 2629 （於開曼群島註冊成立的有限責任公司） C M Y CM MY CY CMY K Mirxes Holding Company Limited (Incorporated in the Cayman Islands with limited liability) Stock Code : 2629 「CRC-1」 指 CRC-1為一種我們正在開發的用於結直腸癌篩查的基於miRNA 的檢測試劑盒 2025年中期報告 Mirxes Holding Company Limited 2 「無症狀」 指 並無產生或顯示症狀 「審核委員會」 指 董事會審核委員會 「BC-1」 指 BC-1為一種根據我們專有RT-qPCR技術用於乳腺癌篩查的基於 miRNA的檢測 「董事會」 指 本公司董事會 「乳腺癌」 指 自乳房發展而來的癌症 「癌症篩查」 指 對並無明顯癌症症狀的個體進行檢查或檢測，以確定此類疾病 的任何潛在跡象或早期階段 「CE-IVD證」 指 表明符合歐盟體外診斷醫療器械法規(IVDR 2017/746)的認證標 誌，其概述有關I ...

9月19日，港股通创新药板块早盘冲高回落后，维持红盘震荡。MIRXES-B一枝独秀，午后一度暴拉 25%，诺诚健华、同源康医药-B大涨超5%居前，权重股信达生物涨超2%。 100%创新药研发标的——港股通创新药ETF（520880）盘初一度上探2.57%，截至发稿仍涨超1%，成 交突破3亿元。 消息面，私募排排网数据显示，截至9月12日，全市场股票私募机构平均仓位超过78%，较9月5日上升 近3个百分点，达到今年最高水平。多家百亿级私募近期透露，目前仓位维持中高水平，并逢低加码创 新药等板块的优质标的。业内人士认为，从长期看，中国优势产业的全球竞争力没有变，中国经济修复 趋势未变，A股和港股的结构性行情有望持续演绎。 对此，港股通创新药ETF（520880）近期资金面有所印证。数据显示，截至9月19日，520880已连续14 日吸金，金额合计近6.8亿元。兴证全球策略首席张忆东日前提示，9月份或是创新药布局良机。 港股通创新药ETF（520880）基金经理丰晨成认为，现在应保持对创新药板块的密切关注，而非"退 场"。短期的市场调整，反而可能给真正质优的创新药企业提供了一次难得的买点。具体来看，当前创 新药仍有 ...

Group 1 - Mirxes-B (2629.HK) experienced a significant price surge, rising over 35% to reach 75 HKD, marking a new all-time high since its IPO [1] - The company's market capitalization has surpassed 20 billion HKD [1] - Since its listing on May 23, the stock price has increased by 220% from the IPO price of 23.3 HKD [1] Group 2 - Mirxes is a Singapore-based company specializing in microRNA technology, focusing on making disease screening and diagnostic solutions accessible in key Asian markets [1] - The company was recently included in the Hang Seng Composite Index, effective from September 8, and has officially become a Hong Kong Stock Connect eligible stock [1]

Core Viewpoint - Mirxes-B (02629) has seen a significant stock price increase, rising over 150% from its IPO price of 23.3 HKD, reaching a high of 59.5 HKD, and currently trading at 54.75 HKD with a trading volume of 566 million HKD [1] Company Overview - Mirxes is a Singapore-based company specializing in microRNA (miRNA) technology, focusing on making disease screening and diagnostic solutions accessible in key Asian markets [1] - The company has one core product, GASTROClearTM, along with two other commercialized products, LUNGClearTM and FortitudeTM, and six candidates in preclinical stages [1] Product Details - GASTROClearTM is a blood-based miRNA detection kit consisting of 12 miRNA biomarkers for gastric cancer screening, which received Class C in vitro diagnostic (IVD) certification from the Health Sciences Authority (HSA) of Singapore in May 2019 and has been successfully commercialized in Singapore [1] Market Inclusion - Mirxes has been included in the Hang Seng Composite Index, effective from September 8, which has contributed to its stock price surge and its designation as a stock eligible for the Shanghai-Hong Kong Stock Connect [1]

Group 1 - Mirxes Holding Limited, a leading cancer early screening company in Singapore, was listed on the Hong Kong Stock Exchange on May 23, 2025, and was included in the Hang Seng Composite Index and Hong Kong Stock Connect within four months, indicating strong international market recognition [1] - For the first half of 2025, Mirxes reported revenue of $10.5 million, a 9.4% increase compared to the same period in 2024, with gross profit reaching $7.1 million, up 51.1%, and gross margin significantly improving from 49.0% to 67.6% [1] - The company's loss decreased by 36.3% year-on-year to $28.23 million, reflecting improved financial performance [1] Group 2 - Mirxes was founded in 2014 and is a global leader in RNA liquid biopsy, focusing on the research of blood cfRNA and cfDNA, while integrating information from proteins, imaging, and epidemiology through multi-dimensional machine learning models [1] - The company has developed its proprietary mSMRT-qPCR technology platform and has conducted multiple studies in early screening for gastric, lung, and breast cancers, with research published in international journals such as Gut, PNAS, and Cancers [1] - In 2020, Mirxes initiated the first national standard for microRNA diagnostics in Singapore, collaborating with prestigious institutions, and is set to be included in the ISO certification system [2] - The company launched the world's first serum gastric cancer molecular diagnostic kit, GASTRO ClearTM, in Singapore in 2019 and was recognized by Nature Biotechnology as the only Asian company on the "Global Liquid Biopsy Innovation Companies" list [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: Mirxes Holding Company Limited (於開曼群島註冊成立的有限責任公司) 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02629 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.00001 | USD | | 100,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | ...

Core Viewpoint - The Hong Kong IPO market is active, with 57 new listings and a total fundraising amount of 131.9 billion HKD as of August 25. However, many companies face challenges in meeting both domestic and Hong Kong regulatory requirements for listing [1]. Group 1: Hong Kong IPO Overview - As of August 25, 2023, there have been 57 new IPOs on the Hong Kong Stock Exchange, raising a total of 131.9 billion HKD [1]. - There are currently 211 companies that have submitted applications for listing in Hong Kong [1]. Group 2: Listing Challenges - Companies looking to list in Hong Kong must comply with both domestic laws and Hong Kong's regulatory framework, making the IPO preparation process complex and demanding [1]. Group 3: Resources for Companies - A compilation of Hong Kong listing rules and disclosure documents for domestic companies planning to list in Hong Kong has been organized to assist businesses in understanding the latest regulatory dynamics [1].

Core Insights - MIRXES-B reported mid-term results for 2025, with revenues of $10.5 million, representing a year-on-year increase of 9.4% [2] - The company's loss attributable to equity shareholders was approximately $28.35 million, narrowing by 36.22% year-on-year, with a loss per share of $0.185 [2] - The revenue growth was primarily driven by increased earnings from GASTROClear and LUNGClear [2]

Core Viewpoint - MIRXES-B (02629) reported a mid-year performance for 2025, showing a revenue of $10.5 million, which represents a year-on-year increase of 9.4% [1] Financial Performance - The company reported a loss attributable to equity shareholders of approximately $28.35 million, which is a reduction of 36.22% compared to the previous year [1] - The loss per share is recorded at $0.185 [1] Revenue Drivers - The increase in revenue is primarily attributed to the growth in earnings from the early detection and precision multi-omics divisions, specifically from GASTROClearTM and LUNGClearTM products [1] - This revenue growth was partially offset by a decrease of $2.6 million in the infectious disease division due to the termination of FortitudeTM product sales [1]

Core Insights - MIRXES-B (02629) reported a mid-year revenue of $10.5 million for 2025, reflecting a year-on-year increase of 9.4% [1] - The company recorded a loss attributable to equity shareholders of approximately $28.35 million, which represents a 36.22% reduction compared to the previous year; the loss per share was $0.185 [1] - The increase in revenue is primarily attributed to the growth in earnings from the early detection and precision multi-omics divisions, specifically from GASTROClear and LUNGClear, which offset a $2.6 million revenue decline in the infectious disease division due to the termination of Fortitude product sales [1]